NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Ethan Chen's et al. second monumental error was embedded in the following
sentence of their review.

"The mOS for the Placebo group was not reported because 90% of subjects
crossed over from the placebo to the DCVax-L group upon determination of
progression (based on MRI) from treatment."

If I understand it correctly, Chen et al. were implying that of the 99 placebos, 90%
(about 89 patients) received DCVax-L after their progression when in fact only
64 of those original 99 placebos received the vaccine after progression. Instead, it was
90% of all 331 trial patients (296 patients) who received DCVax-L, with 232 treatment
patients receiving the vaccine before their progression and 64 receiving the vaccine after
progression.

Is there now any reason why the Ethan Chen group's review should not be withdrawn?